78 related articles for article (PubMed ID: 8740098)
1. Clinical and pharmacokinetic evaluation of a new lipid-based delivery system of amphotericin B in AIDS patients.
Villani P; Regazzi MB; Maserati R; Viale P; Alberici F; Giacchino R
Arzneimittelforschung; 1996 Apr; 46(4):445-9. PubMed ID: 8740098
[TBL] [Abstract][Full Text] [Related]
2. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
Rust DM; Jameson G
Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
[TBL] [Abstract][Full Text] [Related]
3. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
[TBL] [Abstract][Full Text] [Related]
4. Case-control study of amphotericin B in a triglyceride fat emulsion versus conventional amphotericin B in patients with AIDS.
Manfredi R; Chiodo F
Pharmacotherapy; 1998; 18(5):1087-92. PubMed ID: 9758320
[TBL] [Abstract][Full Text] [Related]
5. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases.
Hong Y; Shaw PJ; Nath CE; Yadav SP; Stephen KR; Earl JW; McLachlan AJ
Antimicrob Agents Chemother; 2006 Mar; 50(3):935-42. PubMed ID: 16495254
[TBL] [Abstract][Full Text] [Related]
7. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
Maharom P; Thamlikitkul V
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
[TBL] [Abstract][Full Text] [Related]
8. [Use of amphotericin B in lipid emulsions: does it prevent its toxicity in critically ill patients?].
Hernández G; Altermatt F; Bernucci F; Acuña D; Apablaza F; Valenzuela F; Lefio A; Pérez C; Bugedo G; Castillo L
Rev Med Chil; 2000 Oct; 128(10):1101-7. PubMed ID: 11349508
[TBL] [Abstract][Full Text] [Related]
9. Intrapulmonary disposition of amphotericin B after aerosolized delivery of amphotericin B lipid complex (Abelcet; ABLC) in lung transplant recipients.
Husain S; Capitano B; Corcoran T; Studer SM; Crespo M; Johnson B; Pilewski JM; Shutt K; Pakstis DL; Zhang S; Carey ME; Paterson DL; McCurry KR; Venkataramanan R
Transplantation; 2010 Dec; 90(11):1215-9. PubMed ID: 20881664
[TBL] [Abstract][Full Text] [Related]
10. Effects of amphotericin B incorporated into liposomes and in lipid suspensions in the treatment of murine candidiasis.
Kretschmar M; Nichterlein T; Hannak D; Hof H
Arzneimittelforschung; 1996 Jul; 46(7):711-5. PubMed ID: 8842344
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
[TBL] [Abstract][Full Text] [Related]
12. Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B.
Bellmann R; Cleary JD; Sterba J
Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-8. PubMed ID: 19537331
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
Chakraborty KK; Naik SR
J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435
[TBL] [Abstract][Full Text] [Related]
14. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients.
Peleg AY; Woods ML
J Antimicrob Chemother; 2004 Oct; 54(4):803-8. PubMed ID: 15308606
[TBL] [Abstract][Full Text] [Related]
15. In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin.
Lewis RE; Wiederhold NP; Prince RA; Kontoyiannis DP
J Antimicrob Chemother; 2006 Feb; 57(2):288-93. PubMed ID: 16387749
[TBL] [Abstract][Full Text] [Related]
16. Lipid formulations of amphotericin B.
Dix SP; Andriole VT
Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
[TBL] [Abstract][Full Text] [Related]
17. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.
Cordonnier C; Mohty M; Faucher C; Pautas C; Robin M; Vey N; Monchecourt F; Mahi L; Ribaud P
Int J Antimicrob Agents; 2008 Feb; 31(2):135-41. PubMed ID: 18162375
[TBL] [Abstract][Full Text] [Related]
18. Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections.
Sachs-Barrable K; Lee SD; Wasan EK; Thornton SJ; Wasan KM
Adv Drug Deliv Rev; 2008 Mar; 60(6):692-701. PubMed ID: 18053611
[TBL] [Abstract][Full Text] [Related]
19. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS.
Sharkey PK; Graybill JR; Johnson ES; Hausrath SG; Pollard RB; Kolokathis A; Mildvan D; Fan-Havard P; Eng RH; Patterson TF; Pottage JC; Simberkoff MS; Wolf J; Meyer RD; Gupta R; Lee LW; Gordon DS
Clin Infect Dis; 1996 Feb; 22(2):315-21. PubMed ID: 8838189
[TBL] [Abstract][Full Text] [Related]
20. Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.
Seibel NL; Shad AT; Bekersky I; Groll AH; Gonzalez C; Wood LV; Jarosinski P; Buell D; Hope WW; Walsh TJ
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
